Rankings
▼
Calendar
UTHR Q4 2020 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena
UTHR
United Therapeutics Corporation
$24B
Q4 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$385M
+23.7% YoY
Gross Profit
$350M
91.0% margin
Operating Income
$65M
17.0% margin
Net Income
$99M
25.7% margin
EPS (Diluted)
$2.19
QoQ Revenue Growth
+1.3%
Cash Flow
Operating Cash Flow
$126M
Free Cash Flow
$114M
Stock-Based Comp.
$94M
Balance Sheet
Total Assets
$4.6B
Total Liabilities
$1.2B
Stockholders' Equity
$3.4B
Cash & Equivalents
$739M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$385M
$311M
+23.7%
Gross Profit
$350M
$282M
+24.0%
Operating Income
$65M
$64M
+2.8%
Net Income
$99M
$53M
+87.8%
Revenue Segments
Remodulin
$128M
51%
Orenitram
$74M
29%
Unituxin
$30M
12%
Adcirca
$22M
9%
← FY 2020
All Quarters
Q1 2021 →